Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.
In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.
Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.